In the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial, HDL-elevation with the cholesteryl ester transfer protein (CETP) inhibitor, torcetrapib reduced plasma glucose, insulin and HOMA-IR in patients with diabetes, suggesting that the treatment may have improved insulin sensitivity. Here, INS is linked to diabetes mellitus.